Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 374 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Transplant Recipient (Kidney) Clear all

Conditions: Renal Transplant Recipients With Anti-HLA Antibodies
Interventions: Not listed
Lead sponsor: Databean; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 8
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 5 more

Conditions: Kidney Transplantation
Interventions: Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI; Drug · Biological
Lead sponsor: Singulera Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 3
States / cities: Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota

Conditions: Osteoporosis, Renal Osteodystrophy, Kidney Transplant; Complications
Interventions: Denosumab Inj 60 mg/ml, Placebo; Drug · Other
Lead sponsor: Thomas Nickolas, MD MS; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Chicago, Illinois • Evanston, Illinois • New York, New York

Conditions: Renal Transplantation, Aging
Interventions: 23 valent pneumococcal polysaccharide vaccine, 13 valent conjugated pneumococcal vaccine, Peripheral blood sample; Drug · Biological · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 35 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Charleston, South Carolina

Conditions: Kidney Transplantation
Interventions: Rapamune and Prograf; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
Interventions: RAD001, MMF; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 3
States / cities: Los Angeles, California • Ann Arbor, Michigan • St Louis, Missouri

Conditions: Transplant Complication, CMV
Interventions: Maribavir, Valganciclovir; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Kidney Disease, Liver Disease, Pancreas Disease
Interventions: RIPC by Inflation of Pneumatic Tourniquet; Procedure
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 5 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Renal Transplantation
Interventions: Behavioral Contract; Behavioral
Lead sponsor: University of Tennessee; Other
Eligibility: 21 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications, Liver Transplant Complications, Simultaneous Liver-Kidney Transplantation; Complications
Interventions: Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months; Drug
Lead sponsor: Camille N. Kotton, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Awaiting Organ Transplant, Infection in Solid Organ Transplant Recipients
Interventions: Not listed
Lead sponsor: Michael Ison; Other
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Transplanted Organ Rejection
Interventions: FCR001; Biological
Lead sponsor: Talaris Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 18
States / cities: Phoenix, Arizona • La Jolla, California • San Francisco, California + 14 more

Conditions: Kidney Transplantation
Interventions: Tacrolimus + Ketoconazole, Then Tacrolimus alone, Tacrolimus alone, Then Tacrolimus + Ketoconazole; Drug
Lead sponsor: Sony Tuteja; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Kidney Trasplant
Interventions: Valganciclovir; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hyperlipidemias
Interventions: Evolocumab; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: KidneyTransplant Recipients, Simultaneous Kidney/Pancreas Recipients, Kidney Transplant Donor
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 1,552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 4
States / cities: Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota

Conditions: Transplants and Implants
Interventions: Enteric coated mycophenolate sodium, Mycophenolate mofetil; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Unspecified Complications of Kidney Transplant, Disorder Related to Renal Transplantation
Interventions: Workbook; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: End Stage Renal Disease
Interventions: Expanded Tregs; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Kidney Transplantation, Liver Transplantation, Heart Transplantation, Lung Transplantation, Heart-Lung Transplantation
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 11 Years to 18 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Graft vs Host Disease, Kidney Transplantation
Interventions: Sirolimus (RAPAMUNE); Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 14
States / cities: Los Angeles, California • San Diego, California • Stanford, California + 10 more

Conditions: Kidney Transplant
Interventions: Exercise Rehabilitation; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Kidney Transplantation
Interventions: CFZ533, Tacrolimus (Tac), Mycophenolate mofetil (MMF), Corticosteroids (CS), anti-IL2 Induction; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 6
States / cities: Aurora, Colorado • Baltimore, Maryland • Ann Arbor, Michigan + 3 more

Conditions: Renal Transplantation
Interventions: sirolimus; Drug
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

A Prospective, Global, Multi-center, Treatment Registry Study of Intravenous Immunoglobulin Maintenance Therapy in Alloantibody Positive Renal Allograft Recipients

REgulatory T Cell Therapy to Achieve Immunosuppression REduction

The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients

Pneumococcal Conjugate Vaccine in Aging Renal Transplant

Use of Sirolimus vs. Tacrolimus For African-American Renal Transplant Recipients

Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients

Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients

Remote Ischemic Preconditioning In Abdominal Organ Transplantation

Behavioral Contract Adherence Intervention

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

Cell Mediated Immunity With Risk of Cytomegalovirus (CMV) in Solid Organ Transplant Recipients

A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation

Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients

Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients

Lipid Management in Renal Transplant Recipients Using Evolocumab.

Genomics of Kidney Transplantation

Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients

Evaluation of Sun Protection Education for Kidney Transplant Recipients

Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients

Quality of Life in Pediatric Transplant Recipients

Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients

Effects of Personalized Physical Rehabilitation in Kidney Transplant Recipients

CCFZ533X2201 - PoC Study in de Novo Renal Transplantation

Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic